Dominant gain-of-function mutations of Nav1.7 have been linked to two severe pain syndromes, paroxysmal extreme pain disorder (PEPD) and inherited erythromelalgia (IEM). This evidence concerns the gene SCN9A and paroxysmal extreme pain disorder.